Call for withdrawal of LABA single-therapy inhaler in asthma.
Beasley
Richard
R
Medical Research Institute of New Zealand, Wellington 6242, New Zealand. richard.beasley@mrinz.ac.nz
Perrin
Kyle
K
Weatherall
Mark
M
Wijesinghe
Meme
M
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives; D000730:Androstadienes / Q000008:administration & dosage; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects; D000069502:Budesonide, Formoterol Fumarate Drug Combination; D004338:Drug Combinations; D056736:Drug Recalls; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects; D000068298:Fluticasone; D000068759:Formoterol Fumarate; D006801:Humans; D009330:Nebulizers and Vaporizers; D016032:Randomized Controlled Trials as Topic; D000068299:Salmeterol Xinafoate; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000069502:Budesonide, Formoterol Fumarate Drug Combination; D004338:Drug Combinations; D004983:Ethanolamines; D019819:Budesonide; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol; D000068759:Formoterol Fumarate